Skip to main content
. Author manuscript; available in PMC: 2009 Nov 4.
Published in final edited form as: Cancer Cell. 2008 Nov 4;14(5):408–419. doi: 10.1016/j.ccr.2008.10.011

Figure 7. IL-1RA treatment improves gastric pathology and blocks MDSC recruitment in H. felis infected IL-1β mice.

Figure 7

(A) IL-1RA treatment inhibits the mobilization of MDSCs. Single nucleated cells in peripheral blood were isolated from Line 19 IL-1β transgenic and control mice infected with H. felis for 5 months with or without preventive administration of IL-1RA. Cells were stained with fluorescence-labeled CD11b and Gr-1 antibodies and analyzed by FACS (*p < 0.05, vs untreated mice, n = 6). (B) IL-1RA treatment inhibits the development of gastric inflammation and preneoplasia in H. felis-infected mice. Histopathological scores assessed in mice (*p < 0.05, vs untreated mice, n = 6). Gastric expression of mouse TNF-α and IL-6 (C) and SDF-1α (D) in indicated mice were determined by ELISA. (E) IL-1RA treatment inhibits the development of gastric dysplasia in H. felis-infected IL-1β mice. Stomach sections were from Line 19 IL-1β transgenic and WT mice infected with H. felis for 12 months with or without IL-1RA treatment for 3 months. The histopathologic scores were graded (*p < 0.01, vs untreated mice, n = 10). Error bar in (A)-(E) indicate ± SD.